Table 2 |
|||
|
Clinical and pathological characteristics of the 66 patients, not receiving radiotherapy, with or without the development of local recurrence |
|||
| All |
LR+RT- |
LR-RT- |
|
|
|
|||
| n = 22 |
n = 44 |
||
|
|
|||
| Time to local recurrence, months |
|||
| Median |
35 |
- |
|
| Range |
11–96 |
- |
|
| Follow-up, months |
|||
| Median |
- |
84 |
|
| Range |
- |
21–166 |
|
| Tamoxifen |
2 |
4 |
|
| Chemotherapy |
1 |
1 |
|
| Tamoxifen and chemotherapy |
1 |
0 |
|
| No adjuvant treatment |
18 |
39 |
|
|
|
|||
| Inclusion 1 and 2 |
Inclusion 1 |
Inclusion 1 |
Inclusion 2 |
|
|
|||
| Menopause |
|||
| Pre |
9 |
3 |
4 |
| Post |
13 |
30 |
2 |
| Not available |
0 |
0 |
5 |
| Age at operation, years |
|||
| Median |
53 |
61 |
49 |
| Range |
44–73 |
45–70 |
40–62 |
| Size, millimeters |
|||
| Median |
15 |
13 |
16 |
| Range |
7–30 |
6–40 |
10–26 |
| Not available |
0 |
0 |
0 |
| Grade |
|||
| 1 |
4 |
13 |
5 |
| 2 |
10 |
9 |
3 |
| 3 |
5 |
8 |
3 |
| Not available |
3 |
3 |
0 |
| Estrogen receptor |
|||
| Positive |
14 |
27 |
11 |
| Negative |
8 |
6 |
0 |
| Progesterone receptor |
|||
| Positive |
15 |
17 |
11 |
| Negative |
7 |
14 |
0 |
| Not available |
0 |
2 |
0 |
| Health care region |
|||
| South |
9 |
21 |
11 |
| West |
13 |
10 |
0 |
| South-East |
0 |
0 |
0 |
| Stockholm |
0 |
2 |
0 |
|
|
|||
|
LR-RT- = no local recurrence, no radiotherapy given; LR+RT- = local recurrence developed, no radiotherapy given. |
|||
|
Niméus-Malmström et al. Breast Cancer Research 2008 10:R34 doi:10.1186/bcr1997 |
|||
